Changes in Body Weight and Serum Albumin Levels in Patients Requiring Home Long-term Oxygen Therapy

Purpose: To investigate the long-term changes in body weight and serum albumin levels in patients with respiratory failure, and those with chronic heart failure, who were treated with home long-term oxygen therapy (LTOT) to understand the current status and contribute to future measures. Methods: Patients with chronic obstructive pulmonary disease (COPD), those with interstitial pneumonia (IP), and those with chronic heart failure (CHF) undergoing home LTOT for 6 months or more between January 2011 and January 2019 were included in the study. Body weight and serum albumin levels were assessed at the start of home LTOT and at the end of the observation period, a minimum of 6 months after commencing home LTOT. Results: Sixty-two patients (29 COPDs, 23 IPs, and 10 CHFs) were included. In COPD patients and IP patients, body weight decreased (P = 0.0017, P = 0.0018, respectively, Wilcoxon signed-rank test). Serum albumin levels decreased in IP patients (P = 0.0185) but not in COPD patients. There was neither significant decrease in body weight nor serum albumin levels in patients with CHF. Conclusion: Chronic respiratory failure patients who have home LTOT were likely to have a decreased nutritional status. In order to provide prolonged home LTOT, medical staff need to pay close attention to the nutritional status of patients receiving home LTOT.

Download Full-text

Are COPD Patients with Nocturnal REM Sleep-Related Desaturations More Prone to Developing Chronic Respiratory Failure Requiring Long-Term Oxygen Therapy?

Respiration ◽

10.1159/000056313 ◽

2002 ◽

Vol 69 (2) ◽

pp. 117-122 ◽

Cited By ~ 11

Author(s):

Margherita Sergi ◽

Maurizio Rizzi ◽

Arnaldo Andreoli ◽

Marica Pecis ◽

Claudio Bruschi ◽

...

Keyword(s):

Respiratory Failure ◽

Rem Sleep ◽

Oxygen Therapy ◽

Chronic Respiratory Failure ◽

Copd Patients ◽

Long Term Oxygen Therapy

Download Full-text

Six-year survival of patients with severe respiratory failure treated with long-term oxygen therapy at home

Russian Pulmonology ◽

10.18093/0869-0189-2005-0-1-81-83 ◽

2005 ◽

pp. 81-83

Author(s):

A. R. Tatarsky ◽

A. E. Baskakova

Keyword(s):

Respiratory Failure ◽

Oxygen Therapy ◽

Control Group ◽

Chronic Obstructive ◽

Severe Respiratory Failure ◽

Copd Patients ◽

The Mean ◽

Long Term Oxygen Therapy ◽

At Home

Long-term oxygen therapy (LTOT) improves survival of patients with chronic obstructive pulmonary disease (COPD) having severe respiratory failure and chronic hypoxemia. In our study 51 patients received LTOT at home via concentrators (34 males, the mean age, 65.5 ± 7.8 yrs; 17 females, the mean age, 62.8 ± 4.1 yrs). Of them, 37 (72.5 %) survived 6-year period and 14 died (13 males and 1 female). Causes of death were acute respiratory viral infection (in 1 patient), insult (in 1 patient), chronic heart and lung failure (in 12 patients). Survival of patients with chronic restrictive pulmonary diseases was not longer than 3 years. A control group included 45 COPD patients with severe respiratory failure not receiving LTOT (30 males, the mean age, 66.3 ± 8.5 yrs; 15 females, the mean age, 69.1 ± 4.6 yrs). Of them, 16 survived 6 years and 29 died (5 females, the mean age, 72.6 ± 3.6 yrs, 24 males, the mean age, 67.8 ± 5.2 yrs). So, LTOT at home improves survival of COPD patients with severe respiratory failure.

Download Full-text

Long-Term Oxygen Therapy in COPD: evidences and open questions of current indications

Monaldi Archives for Chest Disease ◽

10.4081/monaldi.2010.311 ◽

2016 ◽

Vol 73 (1) ◽

Author(s):

A. Corrado ◽

T. Renda ◽

S. Bertini

Keyword(s):

Oxygen Therapy ◽

Supplemental Oxygen ◽

Future Research ◽

Chronic Obstructive ◽

Arterial Blood Gas ◽

Arterial Blood ◽

Copd Patients ◽

Number Of Patients ◽

Long Term Oxygen Therapy

Long term oxygen therapy (LTOT) has been shown to improve the survival rate in Chronic Obstructive Pulmonary Disease (COPD) patients with severe resting hypoxemia by NOTT and MRC studies, published more than 25 years ago. The improved survival was found in patients who received oxygen for more than 15 hours/day. The effectiveness of LTOT has been documented only in stable COPD patients with severe chronic hypoxemia at rest (PaO255%. In fact no evidence supports the use of LTOT in COPD patients with moderate hypoxemia (55<PaO2<65 mmHg), and in those with decreased oxygen saturation (SO2<90%) during exercise or sleep. Furthermore, it is generally accepted without evidence that LTOT in clinical practice is warranted in other forms of chronic respiratory failure not due to COPD when arterial blood gas criteria match those established for COPD patients. The prescription of oxygen in these circumstances, as for unstable patients, increases the number of patients receiving supplemental oxygen and the related costs. Comorbidities are likely to affect both prognosis and health outcomes in COPD patients, but at the moment we do not know if LTOT in these patients with complex chronic diseases and mild-moderate hypoxemia could be of any use. For these reasons a critical revision of the actual guide lines indications for LTOT in order to optimise effectiveness and costs, and future research in the areas that have not previously been addressed by NOTT and MRC studies, are mandatory.

Download Full-text